The HDDC2 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human lung adenocarcinoma cell line A-549, engineered to disrupt the endogenous HDDC2 gene. This product provides a heterogeneous pool of gene-edited cells, enabling researchers to study the loss-of-function effects of HDDC2 without clonal selection biases. The polyclonal format ensures representation of diverse editing outcomes, making it suitable for population-level analyses of nucleotide metabolism and cancer cell biology. As a target-gene disruption model, these cells serve as a powerful tool for dissecting the role of HDDC2 in deoxynucleoside triphosphate (dNTP) homeostasis and related cellular processes.
The parental A-549 cell line was originally established from a lung adenocarcinoma resected from a 58-year-old Caucasian male. A-549 cells are widely used as an in vitro model for human lung adenocarcinoma, retaining key features of alveolar type II epithelial cells, including the ability to form confluent monolayers with epithelial barrier function. These cells are also employed to study drug metabolism and transport due to their expression of various phase I and phase II metabolizing enzymes. The A-549 background provides a clinically relevant context for investigating how alterations in nucleotide metabolism intersect with lung cancer biology, particularly given the tumor’s origin from a patient with adenocarcinoma.
HDDC2 encodes a phosphohydrolase that preferentially hydrolyzes dNTPs, acting as a critical regulator of intracellular dNTP pools. Its activity is influenced by cell cycle-dependent kinases and E2F transcription factors, positioning HDDC2 downstream of proliferative signaling. HDDC2 functions in concert with SAMHD1, another dNTPase, and is interconnected with ribonucleotide reductase, composed of RRM1 and RRM2 subunits, which catalyzes the de novo synthesis of dNTPs. Disruption of HDDC2 perturbs this balance, potentially leading to altered dNTP levels that impact DNA replication fidelity and cell cycle progression. By hydrolyzing excess dNTPs, HDDC2 helps maintain the proper substrate supply for DNA polymerases, and its loss may cause replication stress or affect the efficacy of nucleoside analog drugs.
In the A-549 lung adenocarcinoma context, HDDC2 knockout is especially significant for probing cancer metabolism, as tumor cells often exhibit deregulated dNTP pools to sustain rapid proliferation. The epithelial origin of these cells further supports investigations into how nucleotide imbalance affects epithelial barrier integrity and drug sensitivity. This knockout model is instrumental for dissecting the interplay between HDDC2 and other dNTP-regulating factors such as SAMHD1 and ribonucleotide reductase within the nucleotide metabolism network, providing insights into potential vulnerabilities of lung cancer cells.
This polyclonal knockout cell pool is ideally suited for a range of targeted research applications, including the study of nucleotide metabolism dysregulation in lung adenocarcinoma, assessment of dNTP pool dynamics via HPLC quantification, and evaluation of cell cycle alterations through flow cytometry. Researchers can employ these cells to investigate sensitivity to nucleoside analog drugs using viability assays, and to analyze DNA replication stress via EdU proliferation assays and western blotting for HDDC2 protein expression. The model also facilitates RT-qPCR confirmation of HDDC2 mRNA knockdown and functional studies on dNTP hydrolysis. For further technical details or to discuss applications, please contact Ascent Research.
